glp-1+nad+ Science's 2023 Breakthrough: GLP-1R Agonists Premier - GLP-1 and NAD+
Description
It is, it is bad
For more information, book an appointment online or contact us
Thank you for your patience and understanding.
Alongside the elevated risk of acute pancreatitis, no significant differences were identified in the 1-year risk of pancreatic cancer between GLP-1 RA Users and NonGLP-1 RA Users
You can read more about the retraction here
The implications are important
